Opportunities and Challenges of Nested RCTs in IBD Cohorts
Overview
Nested randomized controlled trials (RCTsNC) represent an innovative trial design that integrates randomization within existing cohorts, offering enhanced recruitment, follow-up, and cost efficiencies. Although successfully applied in various medical fields, RCTsNC have yet to be utilized in inflammatory bowel disease (IBD) research, presenting both promising opportunities and notable challenges.
Background
Randomized controlled trials (RCTs) are the gold standard for evaluating medical interventions but face significant operational challenges including complexity, high costs, and recruitment difficulties, especially in IBD. Traditional RCTs often have short follow-up periods limiting long-term safety assessments. Given the increasing prevalence of IBD and knowledge gaps, novel trial designs like RCTs nested in cohorts (RCTsNC) have been proposed to improve trial efficiency and applicability by leveraging existing longitudinal data and cohort infrastructures.
Data Highlights
RCTsNC enable randomization within pre-existing cohorts, using data from research and non-research sources such as electronic health records and registries. This design has demonstrated better patient acceptability, enhanced recruitment, and cost savings compared to traditional RCTs. Most RCTsNC studies have been conducted after 2017 across various interventions but none yet in IBD.
Key Findings
RCTsNC facilitate longer-term safety and efficacy assessments by leveraging existing longitudinal cohort data.
They improve recruitment and follow-up processes through established cohort infrastructures, enhancing patient acceptance.
RCTsNC are more economical than traditional RCTs due to reduced operational complexity and resource use.
Limitations include potential selection bias and challenges in conducting placebo-controlled comparisons within cohorts.
RCTsNC have not yet been formally adopted or endorsed by international drug regulatory agencies for IBD.
This design offers opportunities to study specific IBD subpopulations and environmental exposures difficult to assess in conventional RCTs.
Clinical Implications
Implementing RCTsNC in IBD research could address recruitment challenges and reduce trial costs while enabling more representative and longer-term evaluations of interventions. Clinicians and researchers should consider integrating cohort infrastructures to facilitate nested trials, particularly for studying understudied patient subgroups and lifestyle interventions. Awareness of potential biases and regulatory considerations is essential when designing RCTsNC.
Conclusion
RCTsNC present a promising alternative to traditional RCTs in IBD, offering enhanced efficiency and the potential to fill critical knowledge gaps. Future efforts should focus on adapting this design to IBD and addressing methodological and regulatory challenges to fully realize its benefits.
References
Relton et al. 2010 -- Nested randomized controlled trials: concept and initial applications
Matthews et al. -- Target trial emulation and RCTsNC comparison
Hernan et al. -- Observational data and causal inference
